Gender Difference in 2-Year Mortality and Immunological Response to ART in an HIV-Infected Chinese Population, 2006–2008

Zhihui Dou1, Jiahong Xu2, Jin Hua Jiao2, Ye Ma1, Stephen Durako2, Lan Yu1, Yan Zhao1, Fujie Zhang1∗
1 National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China, 2 Westat Inc., Rockville, Maryland, United States of America

Abstract

Background: Since it was initiated in 2002, the China Free Antiretroviral Treatment (ART) Program has been progressing from an emergency response to a standardized treatment and care system. As of December 31, 2009, a total of 81,880 patients in 31 provinces, autonomous regions, and special municipalities received free ART. Gender differences, however, in mortality and immunological response to ART in this cohort have never been described.

Objective: To understand whether women and men who enrolled in the China National Free ART Program responded equally well to the treatment.

Methods: A retrospective analysis of the national free ART databases from June 2006–December 2008 was performed. HIV-infected subjects who were 18 years or older, ART naïve at baseline, and on a 3TC regimen enrolled in the program from June 1 to December 31, 2006, were included in this study, then followed up to 2 years.

Results: Among 3457 enrolled subjects who met the inclusion criteria, 59.2% were male and 40.8% female. The majority of the subjects were 19–44 years old (77%) and married (72%). Over the full 24 months of follow-up, the mortality rate was 19.0% in males and 11.4% in females (p = 0.0014). Males on therapy for 3–24 months were more likely to die than females (HR = 1.46, 95% CI: 1.04–2.06, p = 0.0307) after adjusting for baseline characteristics. Compared to men, women had higher CD4+ counts over time after initiating ART (p<0.0001).

Conclusions: Our study showed that women had an overall lower mortality and higher CD4+ counts than men in response to ART treatment, which may be attributed to adherence, biological factors, social, cultural and economic reasons. Further study is needed to explore these factors that might contribute to the gender differences in mortality and immunological response to ART.

Introduction

In the past two decades, advances in antiretroviral treatment (ART) have resulted in dramatic declines in death rates in countries where treatment is available, transforming a once-fatal disease into a manageable chronic illness [1–2]. Despite this remarkable achievement, there remain major questions about whether treatment outcomes differ for women and men and what factors may drive such variation. Although a number of studies have examined gender differences in HIV disease progression and in the response to ART, using survival, HIV-1 RNA levels, and lymphocyte subset levels to assess response to treatment, the findings have differed with regard to the association of gender with these measures. Early studies showed a more rapid clinical progression in women, which was attributed to the delay in starting ART and to other gender-related conditions such as discrimination, violence, and stigma [3]. More recently, natural history cohorts observed that early in infection, women have significantly lower amounts of the virus in their blood than do men but suffer the loss of immune cells and develop AIDS just as swiftly as men [4–6]. A cohort study of 2196 HIV infected treatment-naïve adults conducted in South Africa reported that gender was not significantly associated with survival after adjusting for baseline clinical and immunovirological status [7]. Conversely, several studies have found evidence that gender was associated with response to ART [8–11]. Given that HIV/AIDS has affected more women worldwide than any other life threatening infectious disease [12] and that half of the estimated 30.8 million HIV-
infected adults worldwide are women [13], it is critical to have a better understanding of the gender influence in survival and immunological responses to ART. As more and more women are impacted by the HIV epidemic in China [14], it has also become of utmost importance to understand whether women and men respond differently to ART treatment.

In response to the growing HIV epidemic in China, the Chinese government responded in 2002 with a national ART program called the National Free Antiretroviral Therapy Program (NFATP), which provides antiretroviral (ART) drugs free to those most in need [15]. To monitor and evaluate the success of the NFATP, China also established a Free ART Database in 2004 to

Table 1. Demographic and HIV/AIDS Related Characteristics at Baseline by Gender.

|                      | Total (N = 3457) | Male (N = 2047) | Female (N = 1410) | p value^2 |
|----------------------|------------------|-----------------|-------------------|-----------|
| **Gender**           |                  |                 |                   |           |
| Male                 | 2047 (59.20)     |                 |                   |           |
| Female               | 1410 (40.80)     |                 |                   |           |
| **Age (years)**      |                  |                 |                   |           |
| Mean (std. dev.)     | 38.42 (10.17)    | 38.75 (10.15)   | 37.94 (10.17)     |           |
| Median (IQR)         | 37 (31–44)       | 37 (31–44)      | 37 (31–43)        | 0.0544    |
| 19–44                | 2671 (77.35)     | 1574 (77.01)    | 1097 (77.86)      | 0.1007    |
| 45–59                | 642 (18.59)      | 375 (18.35)     | 267 (18.95)       |           |
| ≥60                  | 140 (4.05)       | 95 (4.65)       | 45 (3.19)         |           |
| **Marital Status**   |                  |                 |                   |           |
| Single               | 486 (14.06)      | 397 (19.39)     | 89 (6.31)         | <.0001    |
| Married              | 2475 (71.59)     | 1385 (67.66)    | 1090 (77.30)      |           |
| Divorced             | 214 (6.19)       | 146 (7.13)      | 68 (4.82)         |           |
| Widowed              | 279 (8.07)       | 116 (5.67)      | 163 (11.56)       |           |
| Unknown              | 3 (0.09)         | 3 (0.15)        | 0 (0.00)          |           |
| **Transmission Routes** |            |                 |                   |           |
| FPD                  | 1167 (33.76)     | 586 (28.63)     | 581 (41.21)       | <.0001    |
| IDU                  | 720 (20.83)      | 620 (30.29)     | 100 (7.09)        |           |
| STI                  | 1299 (37.58)     | 676 (33.02)     | 623 (44.18)       |           |
| Other/Unknown        | 271 (7.84)       | 165 (8.06)      | 106 (7.52)        |           |
| **Any Past and/or Current Signs/Symptoms at Enrollment** |            |                 |                   |           |
| Yes                  | 2993 (86.58)     | 1820 (88.91)    | 1173 (83.19)      | <.0001    |
| No                   | 464 (13.42)      | 227 (11.09)     | 237 (16.81)       |           |
| **Baseline AZT Regimen** |            |                 |                   |           |
| Yes                  | 734 (21.23)      | 434 (21.20)     | 300 (21.28)       | 0.9578    |
| No                   | 2723 (78.77)     | 1613 (78.80)    | 1110 (78.72)      |           |
| **CD4+ Counts (cells/μL)** |            |                 |                   |           |
| Mean (std. dev.)     | 125.00 (106.36)  | 117.08 (104.84) | 136.73 (107.54)   |           |
| Median (IQR)         | 109 (36–190)     | 96 (31–180)     | 131 (47–200)      | <.0001    |
| ≥200                 | 674 (21.66)      | 359 (19.32)     | 315 (25.12)       | <.0001    |
| 50–199               | 1496 (48.07)     | 877 (47.20)     | 619 (49.36)       |           |
| <50                  | 942 (30.27)      | 622 (33.48)     | 320 (25.52)       |           |
| **Hemoglobin**       |                  |                 |                   |           |
| Normal or Grade 0    | 2580 (80.65)     | 1607 (84.94)    | 973 (74.45)       | <.0001    |
| Grade 1 or 2         | 504 (15.75)      | 235 (12.42)     | 269 (20.58)       |           |
| ≥Grade 3             | 115 (3.59)       | 50 (2.64)       | 65 (4.97)         |           |
| **Liver Function (AST/ALT)** |            |                 |                   |           |
| ≥100 U/L             | 179 (5.74)       | 140 (7.52)      | 39 (3.10)         | <.0001    |
| <100 U/L             | 2942 (94.26)     | 1721 (92.48)    | 1221 (96.90)      |           |

^1The group frequencies may not sum to total due to missing values.

^2P-values are from Chi-square test for categorical variables and non-parametric test for continuous variables.

doi:10.1371/journal.pone.0022707.t001
collect demographic, treatment, and clinical care information on all patients participating in the NFATP [16]. As of December 2009, the Free ART Database had data from 81,880 patients in 31 provinces and autonomous regions who had received ART through the NFATP [17]. A recent analysis of factors associated with treatment outcome in patients registered in this database suggested a positive association of female gender with good treatment outcome [10], but factors that might explain this association were not explored further. In this study, we extend the previous analysis to examine other factors that might explain the gender-related difference in treatment outcome, using a subset of the NFATP cohort that were treatment naive when entering the program, received initial treatment with a HAART regimen containing 3TC (Lamivudine), and had at least two-year potential follow-up time since initiating therapy.

**Methods**

This analysis was approved by the institutional review board (IRB) of the National Center for AIDS/STD Control and Prevention (NCAIDS), China CDC. Per the IRB review, individual informed consent was waived because this analysis used currently existing data collected during the course of routine treatment and care and data were reported in aggregate without use of individual identifying information.

**Study Design and Population**

As described previously [17,18], the NFATP enrolled HIV-infected subjects who met the national ART treatment guidelines, which includes CD4+ T-cell count <200 cells/μL (≤350 cells/μL in the revised edition in 2008) or World Health Organization (WHO) stage III or IV disease. After enrollment, subjects were followed at week 2, months 1, 2, 3, and then every 3 months thereafter. Clinical information - including clinical signs and symptoms, self-reported adherence, and laboratory test results – were collected at the time of treatment initiation and at each subsequent follow-up visit. WHO staging and TB data were not collected. The local health providers collected these data on site, using standard case report forms and then transferred these data to the national database.

A retrospective analysis was performed on subjects enrolled in the NFATP who had data in the Free ART Database from June 2006-December 2008. Eligible subjects had to be enrolled in the NFATP between June 1–December 31, 2006 to allow for two years of follow-up, at least 18 years of age, ART-naive at time of enrollment, and received a HAART regimen that included 3TC (Lamivudine) as their initial therapy including D4T +3TC+NVP; D4T +3TC +EFV; AZT+3TC +NVP; or AZT+3TC +EFV. A 3TC regimen was required because it became readily available in China in 2005, has lower toxicity than other regimens, and has become the norm for initial therapy in China.

After enrollment, subjects were followed up to 2 years to observe ART response including immunological function (CD4+ counts), side effects to the ART, adherence and mortality. Data from enrollment to visits through December 31, 2008 were included in the analysis to allow the last-enrolled subjects to have up to 2 years of follow-up after treatment initiation. For those who were enrolled earlier, follow-up visits after 24 months were eliminated from this analysis. Subjects with missing gender, missing treatment initiation date, first-line regimen with less than three single drugs or including a combination of AZT+D4T (not allowed due to drug interaction) were excluded from this study. A total of 4791 subjects enrolled into the NFATP from June 1 to December 31, 2006. Of those, 3457 subjects were eligible for this study. When subjects were lost to follow-up or terminated treatment during the two-year follow-up, they were censored from the study, and the length on study was defined as the date of enrollment to the date of the last available visit. Subjects who transferred from one site to another within the program were considered as adherent to study visits.

**Study Measures**

Demographic and baseline characteristics were obtained, including gender, age, marital status, mode of HIV transmission,
signs and symptoms at enrollment, and ART regimens. In this population, the HIV transmissions were mainly through commercial blood donations, noted as the former plasma donor (FPD); intravenous drug use (IDU) and sexually transmitted infection (STI). Laboratory test data included absolute CD4+ cell counts, hemoglobin and liver function, which were collected at baseline and follow-up visits. CD4+ T-cell counts were collected during at least one of the follow-up visits (months 3, 6, 12, 18 and 24). When the CD4+ count was not available for a scheduled follow-up visit, an alternative CD4+ count within ±1.5 months of the scheduled visit time window was used for the analysis. HIV viral load was not available for analysis as a treatment outcome, since the lack of local resources during this time period prevented testing for viral load in most subjects. Based on Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (GSAPAE) for HIV positive subjects only, hemoglobin was categorized as three groups (normal or grade 0: >100 g/dL; grade 1 or 2: 75–100 g/dL; and grade 3+: <75 g/dL), and liver function tests including AST and ALT were categorized as ≥100 U/L vs. <100 U/L (2.5×ULN). Self-reported current signs and symptoms of HIV infection such as fever, diarrhea, rash, fatigue, weight loss and lymphadenopathy, were collected at baseline. Self-reported medication adherence and fourteen self-reported adverse events (including appetite change, vomiting, sleeping difficulties, abdominal pain, dry skin, skin rash, numb limbs, pain limbs, fatigue, body shape change, hair loss, vision change, headache, and vivid dreams) were also collected at follow-up visits. The self-reported medication adherence was collected as an ordinal variable with 0, 1–5, 6–10, 11–15, 16–20 and >20 times missing doses a month, but was redefined as a binary measure (100% vs. <100%) for this study. When a subject did not report having any missing dose, this subject was considered as perfectly adherent to ART medication (100%); otherwise, the subject was considered as less than 100% adherent (a subject reported missing at least one dose during follow-up).

Statistical Analyses

Chi-square was used to examine the differences in proportion of deaths between males and females. Kaplan-Meier survival curves and Log-Rank test were used to display and test gender differences in mortality over 2 years after initiating ART treatment. Univariate and multivariable Cox proportional hazard models were constructed to examine the gender effect on mortality. The demographic and baseline characteristics as well as medication adherence were included as the potential risk factors. The proportional hazard (PH) assumption over time was tested using a graphic approach and time-dependent variables where appropriate. When the PH assumption was not met because of a time/gender interaction, PH models were constructed separately for the subset of subjects who were in the program for up to three months (0–3 months) and for the larger subset who were in the program for up to 24 months (3–24 months). Another subset analysis was conducted among those who had CD4+ counts at baseline and at least three test results available after enrollment. The mixed linear model (MIXED) with repeated measurements was used to examine the effect of gender and other potential covariates on CD4+ count change over time. The unstructured covariance was assumed for the covariance structure on CD4+ counts. Model fit statistics (e.g. AIC, BIC, etc.) were used to choose the best covariance structure.

Results

Demographic and Baseline Characteristics

Among 3457 enrolled subjects who met the inclusion criteria, 59.2% were male and 40.8% females (Table 1). Majority of the subjects were 19–44 years old (77% for both genders), married (68% for males and 77% for females). Among all transmission routes, sexual transmission was the most frequent for both males and females (33% for males and 44% for females), followed by IDU for males (30%) and FPD for females (41%). Over two-thirds of all subjects had experienced signs/symptoms of HIV infection, but men had significantly more occurrences (89% vs. 83%, p<0.001). The median baseline CD4+ counts were lower for men compared with women (96 vs. 131 cells/μL, p<.0001) and more men than women had CD4+ counts <50 cells/μL at enrollment (33.5% vs. 25.5%, p<0.0001). More females had a grade 1 or higher abnormal hemoglobin (26%) but more males had abnormal liver function (≥100 U/L at baseline (8%), Among 3457 patients, 136 (3.9%) were lost to follow-up and 99 (2.9%) terminated ART (Figure 1). No subjects transferred out of the program. The median follow-up time for both male and female subjects was 21.3 months.

Two-Year Mortality

Overall, 443 (12.8%) of 3457 subjects were died in the first two years after initiating ART treatment. Among them, 151 (10.7%) of 1410 females and 292 (14.3%) of 2047 males were died. A significantly greater death incidence from Kaplan-Meier (KM) estimates in males 24 months after enrollment was detected when compared with female subjects (19.0% vs. 11.4%, p = 0.0014). The estimated two-year overall survival rate, unadjusted for covariates, was 84.3%; two-year survival rate for females was significantly higher than for males (Figure 2, 88.6% vs. 81.0%, p = 0.0014).

We observed that mortality was higher during the early phase of the treatment (0–3 months). Of the 443 deaths observed in the first two years, about 248 (56%) occurred in the first three months after ART initiation. In addition, for multivariate analysis adjusting for covariates, the PH assumption of constant hazard was not satisfied over the entire 24-month period. There was a time/gender interaction (p = 0.0411), with the hazard rate for females changing over time. Therefore, the separated analyses were further performed: those in the program for 0–3 months and those in the program for greater than 3 months. The PH assumption was satisfied for these two separate groups. There was no difference in survival between males and females among those early deaths (Figure 3, Panel A). In contrast, for the other 195 (44%) subjects who died after three months, the survival rate for females was significantly higher than for males (Figure 3, Panel B). The results from the multivariable Cox models showed that there was no evidence of gender effect on early mortality (p = 0.0040) but males were at greater risk of dying after being on treatment for at least three months ($HR = 1.46$, 95% CI: 1.04–2.06, $p = 0.0307$) after adjusting for HIV transmission routes, baseline and current signs and symptoms, and baseline CD4+ counts (Table 2). Although gender was not associated with the mortality during the early stage of treatment (0–3 months), there was a strong association with mortality for two other covariates (having baseline signs/symptoms and lower CD4+ counts) in this early period even stronger than later in treatment (3–24 months).

CD4+ T-Cell Count Response to ART Treatment

CD4+ T-cell count was examined to assess gender differences in immunological response to ART. Due to limited resources, CD4+ counts were only done at a few visits for some subjects. Thus, we were unable to adjust for CD4+ cell count change over time in the multivariate proportional hazard models described earlier. We were, however, able to make inferences on CD4+ change over time for subjects who had baseline and at least 3 follow-up CD4+ count test results. The results from the multivariable mixed model with repeated measurements indicated that the average CD4+ cell count change over time in males was significantly lower than in...
females \(p<0.0001\) after adjusting for other factors including being older, infected through FPD, having past and current signs and symptoms, lower baseline CD4+ counts, without abnormal liver function, and less than 100% ART adherence (Table 3).

### Self-Reported Adverse Events

We attempted to examine the self-reported adverse events at the selected follow-up visits (months 3, 6, 12, 18, and 24). When the events were missing at a specific month, the imputation was made by using an available data point within \(\pm 1.5\) months around that specific follow-up visit. The results indicated that females tended to report more adverse events at most follow-up visits. For example, the overall proportion of self-reporting at least one adverse event among females was significantly higher than males at 3 months (28.7% vs. 23.5%, \(p=0.0019\)), 6 months (23.5% vs. 19.0%, \(p=0.0053\)), and 12 months (18.6% vs. 14.7%, \(p=0.0095\)).

### Discussion

Our current study on this homogenously-treated population confirmed that females have better survival at 2 years on ART than men do. Compared to men, females had overall better survival.
immunological response overtime while on ART. Our findings are consistent with others. Hall et al [8], using data from the CDC national HIV/AIDS reporting system from 1996 to 2001, observed that the risk for progression from HIV to AIDS or death was greater for nonwhites, men, and older persons compared with whites, women, and younger persons, respectively. Collazos et al [9] found that women had better clinical and viro-

### Table 2. Relationship of HIV/AIDS Mortality with Demographic and HIV/AIDS Related Characteristics.

| Overall (N = 3457) | On Treatment for <3 Months (N = 456) | On Treatment for 3–24 Months (N = 3001) |
|-------------------|--------------------------------------|----------------------------------------|
|                   | Unadjusted  | HR (95% CI)                      | Unadjusted  | HR (95% CI)                      | Unadjusted  | HR (95% CI)                      |
| Died/n (%)        |            |                                |            |                                |            |                                |
| Gender            |            |                                |            |                                |            |                                |
| Male              | 292/2047 (14.26) | 1.38 (1.13–1.68)           | 1.12 (0.86–1.45) | 1.31 (0.95–1.81)   | 1.56 (1.15–2.11) | 1.46 (1.04–2.06)                   |
| Female            | 151/1410 (10.71) | 1.00                            | 1.00                            | 1.00                            | 1.00                            | 1.00                            |
| Age (years)       |            |                                |            |                                |            |                                |
| 19–44             | 330/2671 (12.35) | 1.00                            | 1.00                            | 1.00                            | 1.00                            | 1.00                            |
| 45–59             | 86/642 (13.40)    | 1.05 (0.83–1.33)           | 1.34 (0.95–1.68)           | NS                              | 1.26 (0.90–1.77)             | NS                              |
| ≥60               | 27/140 (19.29)     | 1.64 (1.11–2.43)           | 1.22 (0.74–2.01)           | NS                              | 1.47 (0.77–2.79)             | NS                              |
| Marital Status    |            |                                |            |                                |            |                                |
| Single            | 55/486 (11.32)     | 1.00                            | 1.00                            | 1.00                            | 1.00                            | 1.00                            |
| Married           | 309/2475 (12.48)    | 1.03 (0.78–1.38)           | 1.16 (0.79–1.71)           | NS                              | 0.97 (0.64–1.49)             | NS                              |
| Divorced          | 44/214 (20.56)     | 1.87 (1.26–2.78)           | 1.02 (0.61–1.71)           | NS                              | 1.54 (0.82–2.88)             | NS                              |
| Widowed           | 35/279 (12.54)      | 1.05 (0.69–1.61)           | 1.44 (0.80–2.60)           | NS                              | 1.08 (0.58–2.00)             | NS                              |
| Transmission Routes|            |                                |            |                                |            |                                |
| FPD               | 169/1167 (14.48)    | 1.00                            | 1.00                            | 1.00                            | 1.00                            | 1.00                            |
| IDU               | 96/720 (13.33)      | 1.00 (0.78–1.28)           | 0.40 (0.27–0.58)           | 0.54 (0.35–0.84)             | 1.28 (0.90–1.80)             | 1.27 (0.87–1.85)             |
| STI               | 144/1299 (11.09)    | 0.78 (0.62–0.97)           | 0.76 (0.57–1.02)           | 0.78 (0.54–1.12)             | 0.57 (0.40–0.82)             | 0.57 (0.39–0.84)             |
| Other/Unknown     | 34/271 (12.55)      | 0.91 (0.63–1.31)           | 0.93 (0.58–1.46)           | 0.91 (0.54–1.54)             | 0.63 (0.33–1.18)             | 0.55 (0.27–1.12)             |
| Any Past and/or Current Signs/Symptoms at Enrollment | | | | | | |
| Yes               | 428/2993 (14.30)    | 4.79 (2.86–8.01)           | 5.66 (1.81–17.66)          | 5.71 (1.39–23.39)             | 2.66 (1.49–4.78)             | 1.91 (1.02–3.57)             |
| No                | 15/464 (3.23)       | 1.00                            | 1.00                            | 1.00                            | 1.00                            | 1.00                            |
| CD4+ Counts       |            |                                |            |                                |            |                                |
| ≥200              | 26/674 (3.86)        | 1.00                            | 1.00                            | 1.00                            | 1.00                            | 1.00                            |
| 50–199            | 145/1496 (9.69)      | 2.51 (1.66–3.82)           | 3.50 (1.60–7.66)           | 3.48 (1.58–7.67)             | 1.98 (1.20–3.25)             | 1.95 (1.18–3.21)             |
| <50               | 188/942 (19.96)      | 5.70 (3.78–8.59)           | 5.66 (2.63–12.18)          | 4.60 (2.11–10.06)             | 3.14 (1.90–5.21)             | 3.04 (1.82–5.07)             |
| Hemoglobin        |            |                                |            |                                |            |                                |
| Normal or Grade 0 | 263/2580 (10.19)     | 1.00                            | 1.00                            | 1.00                            | 1.00                            | 1.00                            |
| Grade 1 or 2      | 100/504 (19.84)      | 2.13 (1.69–2.69)           | 1.35 (1.00–1.82)           | NS                              | 1.59 (1.10–2.29)             | NS                              |
| ≥Grade 3          | 32/115 (27.83)       | 3.25 (2.25–4.69)           | 2.14 (1.37–3.35)           | NS                              | 1.91 (0.97–3.76)             | NS                              |
| Liver Function: AST/ALT | | | | | | |
| ≥100 U/L          | 37/179 (20.67)       | 1.95 (1.39–2.74)           | 1.35 (0.86–2.10)           | NS                              | 1.83 (1.08–3.11)             | NS                              |
| <100 U/L          | 341/2942 (11.59)     | 1.00                            | 1.00                            | 1.00                            | 1.00                            | 1.00                            |
| Self-reported ART Adherence | | | | | | |
| 100%              | 267/2444 (10.92)     | 1.18 (0.92–1.52)           | 1.14 (0.75–1.72)           | NS                              | 0.91 (0.66–1.25)             | NS                              |
| <100%             | 78/819 (9.52)        | 1.00                            | 1.00                            | 1.00                            | 1.00                            | 1.00                            |

1HR: hazard ratio; NS: the covariate was either statistically insignificant (not entered into the initial full multivariable Cox model) or deleted during the model selection procedure; the proportional hazard assumption was tested using graphic approach (univariate model only) and time-dependent variable (both univariate and multivariable models).

2The PH-assumption for the univariate model (gender) among all subjects was satisfied (p = 0.3000) but was violated for the overall multivariate final model (p = 0.0411).

3The PH-assumption was satisfied for 0–3 months (p = 0.6228) and 3–24 months (p = 0.0497) final multivariable models. The R-square for the final multivariable models are 86% for 0–3 months and 12% for 3–24 months.

doi:10.1371/journal.pone.0022707.t002

immunological responses than men and concluded that gender played a small but significant role in outcome. An observational study conducted in the US reported that lower pre-therapy CD4+ cell count, younger age, and female sex were all factors associated with increased CD4+ cell count gains from month 3 to year 4 of ART [3]. A recent study performed in Uganda and Zimbabwe on the virologic and immunologic outcomes of 300 HIV-infected
adults treated with nucleoside reverse transcriptase inhibitors (NRTIs), women showed a 2.3 fold higher rate of virologic suppression compared with men after 48 weeks on ART [11].

Our finding that mortality did not differ by gender in the first 3 months on treatment may suggest that a certain proportion of patients entered therapy at a late enough stage of disease progression that there is little opportunity for therapy to work. This hypothesis is supported by our findings that mortality was much higher in the first 3 months and that it was strongly associated with greater baseline signs/symptoms and lower baseline CD4+ counts. After 3 months the hazard rate of females diverged from that of males.

There are a number of possible explanations for our findings: (1) biologically better response to the drugs; (2) better adherence to treatment; and (3) other factors such as co-morbid conditions, general health status, and psychosocial differences. Our analysis, together with the recent findings of Rotger, et al. [19], Heath, et al. [20], and Van, et al. [21], suggest that there may be a real difference between females and males in biological response to the ARTs. Because the NFATP data are from a registry, we had limited items that measured co-morbidity, general health status, and psychosocial factors. While a higher proportion of males had abnormal liver function, suggesting possible co-infection with hepatitis B or C, this did not explain the treatment response difference. Males were also much more likely to have been infected through injection drug use, suggesting both poorer overall health status and poorer psychosocial status. Our results suggest that there may be very different factors influencing early and later

Table 3. Impact of Gender and Other Factors on Immunology Responses to ART Treatment Over Time among 996 Subjects.

|                          | Unadjusted | p-value | Adjusted   | p-value |
|--------------------------|------------|---------|------------|---------|
|                          | Est. Coef. (Std. Err.)¹ |         | Est. Coef. (Std. Err.)¹ |         |
| Gender                   |            |         |            |         |
| Male                     | −33.34 (4.79) | <.0001  | −22.11 (4.79) | <.0001  |
| Female                   | 0.00       | 0.00    | 0.00       | 0.00    |
| Age (years)              |            |         |            |         |
| ≥60                      | −42.72 (12.53) | 0.0007  | −30.70 (12.81) | 0.0166  |
| 45–59                    | −25.22 (5.93) | <.0001  | −15.07 (5.77) | 0.0091  |
| 19–44                    | 0.00       | 0.00    | 0.00       | 0.00    |
| Marital Status           |            |         |            |         |
| Widowed                  | −0.81 (10.75) | 0.9397  | NS         |         |
| Divorced/Separated       | 7.46 (11.68) | 0.5230  | NS         |         |
| Married/Live Together    | −13.75 (6.90) | 0.0465  | NS         |         |
| Single                   | 0.00       | 0.00    | 0.00       | 0.00    |
| Transmission route       |            |         |            |         |
| Other                    | 15.83 (8.75) | 0.0704  | 33.43 (8.50) | <.0001  |
| STI                      | 20.71 (5.59) | 0.0002  | 30.26 (5.63) | <.0001  |
| IDU                      | 46.35 (7.51) | <.0001  | 42.40 (7.74) | <.0001  |
| FPD                      | 0.00       | 0.00    | 0.00       | 0.00    |
| Any Past and/or Current Signs/Symptoms | | | | |
| Yes                      | −59.89 (6.19) | <.0001  | −14.36 (6.06) | 0.0179  |
| No                       | 0.00       | 0.00    | 0.00       | 0.00    |
| Baseline CD4+ Counts (cell/uL) | | | | |
| <50                      | −212.6 (6.44) | <.0001  | −205.1 (7.04) | <.0001  |
| 50–199                   | −111.8 (5.81) | <.0001  | −104.4 (6.14) | <.0001  |
| ≥200                     | 0.00       | 0.00    | 0.00       | 0.00    |
| Hemoglobin               |            |         |            |         |
| Grade 3 & Grade 4        | −61.59 (14.63) | <.0001  | NS         |         |
| Grade 1 & Grade 2        | −61.44 (6.67) | <.0001  | NS         |         |
| Normal & Grade 0         | 0.00       | 0.00    | 0.00       | 0.00    |
| Liver Function (AST/ALT) |            |         |            |         |
| Yes                      | 27.74 (12.24) | 0.0235  | 24.95 (11.08) | 0.0244  |
| No                       | 0.00       | 0.00    | 0.00       | 0.00    |
| Self-Reported ART Adherence |        |         |            |         |
| 100%                     | 11.87 (5.51) | 0.0313  | 11.46 (5.20) | 0.0277  |
| <100%                    | 0.00       | 0.00    | 0.00       | 0.00    |

¹Est. Coef.: estimated coefficient; Std. Err.: standard error.

doi:10.1371/journal.pone.0022707.t003
mortality, which merits further detailed laboratory investigation, since it might reveal genetic or other biological markers that would improve the personalization of treatment regimens for both women and men.

Our study has limitations because of the nature of the information that was retrospectively obtained from the Free ART database from 31 provinces of China, certain levels of recall bias and measurement variations may be introduced in data collection. Second, HAART initiation relies on both WHO staging and CD4+ count; however, WHO stage data was not collected until 2010. Although signs/symptom data were analyzed, this may not truly reflect WHO stage. Third, we were not able to analyze viral load response because it was infrequently collected in the field. Fourth, the CD4+ analysis was restricted to the subjects who had CD4 tests 3 times or more after the treatment initiation. Although the demographic characteristics (e.g., gender, age, and marital status) from this subset were comparable to the rest of the population, this subset may not truly represent the entire population of subjects who were included in the analysis. Fifth, self-reported treatment adherence data may not be completely accurate, and it is possible that some treatment response differences might still be attributable to differences in adherence. Finally, we had limited information collected on other possible explanatory factors, such as co-morbidities, general health, and psychosocial status.

Our findings of lower mortality rates among females after 3 months on ART and better immunological response among females in a subset of our cohort demonstrate a difference in outcomes between men and women in the first 2 years of treatment with ART. Given the limitation of data it is unclear whether this is due to environmental, psychological, or biological factors. Further controlled prospective data collection should be undertaken to determine whether biological factors related to gender play an important role in determining outcomes to treatment. Further prospective studies within our own treatment cohort are necessary to explore other possible explanatory factors such as adherence, co-morbidities, general health status and psychosocial factors.

Recommendations: Viral load is a gold standard to evaluate whether patients are virologically suppressed after ART. It is important to collect viral load data at certain time points after ART. Intensive adherence counseling for patients on failing regimens would increase the optimization of first line regimens and save money in the long term.

Author Contributions
Conceived and designed the experiments: ZD JX JHJ FZ. Analyzed the data: ZD JX. Contributed reagents/materials/analysis tools: ZD YM FZ. Wrote the paper: JX JHJ SD. Critically reviewed the manuscript and approved the final version: FZ ZD JX YM SD LY YZ.

References
1. Jain MK, Skisht DJ, Cloud JW, Jain CL, Burns D, et al. (2003) Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient death in 1995 and in 1999-2000. Clin Infect Dis 36: 1030–1038.
2. Van Sighem AI, Van de Wiel MA, Ghanece AC, Jambres M, Reiss P, et al. (2003) Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 17: 2227–2236.
3. Moore J, Schuman P, Schoenbaum E, Boland B, Solomon L, et al. (1999) Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America. AIDS 13: 2459–68.
4. Sterling T, Vlahov D, Ateshian J, Hoover DR, Margolick JB, et al. (2001) Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 344(10): 720–725.
5. Anastas K, Gange SJ, Lau B, Wiener B, Detels R, et al. (2000) Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr 24(3): 216–226.
6. Nicastri E, Angelletti C, Palmisano L, Sarmati L, Chiesi A, et al. (2005) Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 19: 577–583.
7. Cornel M, Myer L, Kaplan R, Bekker L-G, Wood R (2009) The impact of gender and income on survival and retention in a south african antiretroviral therapy program. tropical Med & Inter Heal 14(7): 722–731.
8. Hall HI, McDavid K, Leng Q, Sloggett A (2006) Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001. Ann Epidemiol Nov 16(13): 824–833.
9. Collazos J, Asensio V, Carton JA (2007) Sex difference in the clinical, immunological and virological parameters of HIV infected patients treated with HAART. AIDS 21: 435–441.
10. DART Virology Group and Trial Team (2006) Virologic response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 20: 1391–1399.
11. Alibhai A, Kipp W, Saunders LD, Rubale T (2010) Gender-related mortality for HIV-infected patients on highly active antiretroviral therapy(HAART) in rural. Uganda International Journal of Women’s Health 2: 45–52.
12. Quinn TC, Overbaugh J (2005) HIV/AIDS in women: an expanding epidemic. Science 308: 1582–1583.
13. UNAIDS, WHO (2007) AIDS epidemic update: December 2007. UNAIDS/ 07.27E/EC 1322E. pp 12–11-2007.
14. Chinese Ministry of Health (2009): http://www.gov.cn/jrzg/2009-12/01/content_1477101.htm.
15. Wu Z, Sullivan SG, Wang Y, Rouheram-Bousu MJ, Detels R (2007) Evolution of China’s response to HIV/AIDS. Lancet 369(9562): 679–690.
16. Zhang F, Pan J, Yu L, Wen Y, Zhao Y (2005) Current progress of China’s free ART program. Cell 15(11–12): 877–882.
17. Ma Y, Zhang F, Zhang C, Zhao Y, Zhao D, et al. (2009) Cohort Profile: The Chinese national free antiretroviral treatment cohort. Int J Epidemiol. pp 1–7.
18. Zhang F, Dou Z, Ma Y, Zhao Y, Liu Z, et al. (2009) Five-year outcomes of the China national free antiretroviral treatment program. Ann Intern Med Vol 151(4): 241–51.
19. Rotger M, Casaja C, Teleni A (2006) Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents. Curr HIV/AIDS Rep 3(3): 118–125.
20. Heath KV, Chan KJ, Singer J, O’Shaughnessy MV, Montaner JS, et al. (2002) Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy. Int J Epidemiol 31(5): 1016–1020.
21. Van LF, Andrews S, Grimuetzein B, Williams E, Lazunas MK, et al. (2005) The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 19(5): 463–471.